Menu
No results found.
BAFNAPH
Bafna Pharmaceuticals Limited – NSE
📢 Scheduled Break in Updates
Please note that there will be no updates this week as I am taking a well-deserved holiday. Normal updates will resume on Saturday, 30th August. Thank you for your understanding.
Weekly Share Price & Valuation Overview
Market Overview
Open
114.8900
Close
114.8900
High
114.8900
Low
109.9000
Trend
0.70012
Bafna Pharmaceuticals Limited
India
• NSE - National Stock Exchange of India
• BAFNAPH
• Currency: INR
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, and internationally. The company was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited operates as a subsidiary of SRJR Lifesciences LLP.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- INR 2.48B
- Enterprise Value Operating value: market cap + total debt − cash.
- INR 2.83B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- INR 1.47B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- INR 468.13M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- INR 150.82M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- INR 62.14
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 3.50
- Shares Outstanding
- 23.66M
- Float Shares
- 4.51M
- Implied Shares Outstanding
- 23.89M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
10.68%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
10.25%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
31.80%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
5.62%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Year-over-year revenue growth.
-
4.00%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
1.29%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.33
- Total Cash Cash and equivalents.
- INR 34.33M
- Total Debt Short + long-term interest-bearing debt.
- INR 281.99M
- Net Debt Total debt − cash (negative = net cash).
- INR 247.66M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 1.87
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 3
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 1
Operational quality/consistency (0–3, higher is better).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
19.1%
Insiders
Shares held by company insiders (officers, directors).
87.8%
Institutions
Shares held by institutions (funds, pensions).
—
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
1.0%
Net Debt
Total debt − cash (negative = net cash).
INR 247.66M
16.8% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
71
Methodology Notes
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
As of: 2025-08-27 10:32
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.